Xu G, Kaneto H, Lopez-Avalos MD, Weir GC, and Bonner-Weir S
The epidemiology and pathophysiology of diabetic HFpEF DM, a common comorbidity in patients with HFpEF, is also the major risk factor for HFpEF [15]
Safety Considerations and Kidney Monitoring During GLP-1 Treatment While GLP-1 medications demonstrate kidney-protective benefits, existing kidney disease requires careful baseline assessment before starting therapy
in other words, they were more likely to deeply engage with off-task distractions compared with placebo (Jaswal 2019)
A hypoketotic result (low blood sugar with no ketones) is a major red flag for an SPCD crisis [1] [14]
In the brain, semaglutide acts on areas that regulate appetite and food intake, particularly the hypothalamus and reward centres, leading to reduced hunger, increased feelings of fullness, and potentially decreased food cravings